Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials.
Bo AhrénStephen L AtkinGuillaume CharpentierMark L WarrenJohn P H WildingSune BirchAnders Gaarsdal HolstLawrence Alan LeiterPublished in: Diabetes, obesity & metabolism (2018)
In SUSTAIN 1 to 5, semaglutide-induced weight loss was consistently greater versus comparators, regardless of baseline BMI. The contribution of nausea or vomiting to this weight loss was minor.